GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 494
- Registration Number
- NCT01456325
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01442090
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2012-01-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT01442064
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT01437566
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01432353
A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT01423539
A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers
- First Posted Date
- 2011-08-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01423318
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Completed
- Conditions
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01422265
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT01418222
- Locations
- 🇺🇸
Ingalls Cancer Research Center, Harvey, Illinois, United States
🇺🇸Toledo Comm. Onc. Program, Toledo, Ohio, United States
🇺🇸Virginia Cancer Institute, Richmond, Virginia, United States
A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01414205
- Locations
- 🇺🇸
Arizona Oncology, Tucson, Arizona, United States
🇺🇸Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States
🇺🇸Arizona Clinical Research Ctr, Tucson, Arizona, United States
© Copyright 2024. All Rights Reserved by MedPath